Balance Sheet
Cash Flow Statement
Amortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$20.0 million.

  • Legend Biotech's Cash from Investing Activities fell 106.08% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 95.29%. This contributed to the annual value of -$850.5 million for FY2024, which is 1016.67% down from last year.
  • As of Q3 2025, Legend Biotech's Cash from Investing Activities stood at -$20.0 million, which was up 87.92% from -$165.5 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash from Investing Activities peaked at $407.5 million during Q4 2023, and registered a low of -$695.6 million during Q2 2024.
  • In the last 3 years, Legend Biotech's Cash from Investing Activities had a median value of -$87.8 million in 2024 and averaged -$62.4 million.
  • The largest annual percentage gain for Legend Biotech's Cash from Investing Activities in the last 5 years was 1,534.48% (2023), contrasted with its biggest fall of 4,807.27% (2023).
  • Quarterly analysis of 5 years shows Legend Biotech's Cash from Investing Activities stood at $96.5 million in 2021, then plummeted by 74.17% to $24.9 million in 2022, then spiked by 1,534.48% to $407.5 million in 2023, then tumbled by 121.56% to -$87.8 million in 2024, then tumbled by 106.08% to -$20.0 million in 2025.
  • Its last three reported values are -$20.0 million in Q3 2025, -$165.5 million for Q2 2025, and $256.6 million during Q1 2025.